Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

Home/Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

Pharmaceutical Manufacturing, Pharmacy, Pharma & Healthcare

Publication ID:

GBI0717005

Publication Date:

July 01, 2017

Pages:

136

Publisher:

GBI Research

Region:

Global

$4,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis

Summary

Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 types of dermatological conditions are thought to exist, ranging from the autoimmune disorder psoriasis to the very common condition acne vulgaris. The scope of dermatological disorders is diverse in terms of severity and clinical presentation, and if a condition is not sufficiently kept under control, it can significantly impair the patient’s quality of life.

The treatment landscape for dermatological disorders was traditionally dominated by genericized topical therapies such as glucocorticoids and retinoids. The approval of monoclonal antibodies (mAbs) such as Humira, Enbrel and Remicade for psoriasis revolutionized both the management of psoriasis and the dermatology therapy area. These first generation mAbs are now off-patent and have biosimilar versions approved by the FDA, but in recent years the therapy area has seen a number of new mAbs enter the market. These new approvals will provide patients with more treatment options and stimulate growth in the therapy area. In 2017 Dupixent became the first biologic to be approved for atopic dermatitis, expanding the use of biologics to an indication other than psoriasis.

Overall there are 871 products being actively developed in the dermatology pipeline, but these include products being developed for many smaller indications. The indications with the largest pipelines are psoriasis, atopic dermatitis and acne vulgaris, which contain 282, 136 and 70 products, respectively.

Scope

- Global revenue from the dermatology market is forecast to increase from $19.8 billion in 2016 to $36.6 billion in 2023, at a compound annual growth rate of 9.13%. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- What are the leading companies in terms of market share?
- Which companies are forecast to experience the largest growth in market share?
- Which companies rely heavily on revenue derived from antibacterial drugs?
- How will the market respond to recent approvals?
- Will generics and biosimilars have a significant impact on the market over the forecast period?
- What class of drugs dominate the market?
- What molecular targets are most popular in the pipeline?
- What are the commercial prospects for the most promising late-stage products?

Reasons to buy

- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the dermatology pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- This review also provides a detailed look at dermatology product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
- Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
- Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 10
2.1 Therapy Area Introduction 10
2.2 Symptoms 10
2.3 Etiology and Pathophysiology 11
2.3.1 Atopic Dermatitis 11
2.3.2 Acne Vulgaris 13
2.3.3 Psoriasis 14
2.4 Co-morbidities and Complications 14
2.5 Diagnosis, Scales and Grading 15
2.5.1 Atopic Dermatitis 15
2.5.2 Acne Vulgaris 16
2.5.3 Psoriasis 17
2.6 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 17
2.6.1 Atopic Dermatitis 18
2.6.2 Acne Vulgaris 19
2.6.3 Psoriasis 20
2.7 Treatment 21
2.7.1 Topical Corticosteroids 22
2.7.2 Calcineurin Inhibitors 23
2.7.3 Retinoids 23
2.7.4 Systemic Immunosuppressive Agents 24
2.7.5 Biologics 25
2.7.6 Antihistamines 25
2.7.7 Hormonal Therapy 26
2.7.8 Moisturizers 26
3 Key Marketed Products 27
3.1 Overview 27
3.2 Humira (adalimumab) - AbbVie 27
3.3 Remicade (infliximab) - Johnson & Johnson 29
3.4 Enbrel (etanercept) - Amgen 31
3.5 Stelara (ustekinumab) - Johnson & Johnson 33
3.6 Neoral (cyclosporine) - Novartis 34
3.7 Protopic (tacrolimus) - Astellas Pharma 36
3.8 Cosentyx (Secukinumab) - Novartis 37
3.9 Dupixent (dupilumab) Sanofi and Regeneron 39
3.10 Taltz (ixekizumab) - Eli Lilly 41
3.11 Eucrisa (crisaborole) - Pfizer 43
3.12 Siliq (Brodalumab) - Valeant Pharmaceuticals 44
3.13 Elidel (pimecrolimus) 46
3.14 Elocon (mometasone furoate) 46
3.15 Differin (adapalene) 47
3.16 Metolate (methotrexate) 48
3.17 Clobex (clobetasol propionate) 48
3.18 Conclusion 49
4 Pipeline Landscape Assessment 50
4.1 Overview 50
4.2 Molecule Types in the Pipeline 53
4.3 Molecular Targets in the Pipeline 54
4.4 Clinical Trials 56
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 57
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 61
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 65
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 69
4.4.5 Assessment of Key Pipeline Products 72
4.5 Conclusion 78
5 Multi-scenario Market Forecast to 2023 79
5.1 Overall Market Size 79
5.2 Generic Penetration 81
5.3 Revenue Forecast by Molecular Target 82
5.3.1 Tumor Necrosis Factor-Alpha 82
5.3.2 Interleukins 1, 4, 5, 12, 17 and 23 and Receptors 83
5.3.3 Calcineurin 85
5.3.4 Glucocorticoid Receptors 86
5.3.5 Phosphodiesterase 4 87
6 Company Analysis and Positioning 88
6.1 Revenue and Market Share Analysis by Company 89
6.1.1 Novartis - Will Revenue from Cosentyx Continue to Increase in the Forecast Period? 94
6.1.2 AbbVie - Will Humira’s Patent Expiry Lead to Loss of Market Leadership? 95
6.1.3 Johnson & Johnson - Guselkumab and Stelara Fail to Offset Revenue Lost from Remicade 96
6.1.4 Sanofi - High Revenue Growth from Dupixent Will See Sanofi’s Revenue from the Dermatology Therapy Area Increase 97
6.1.5 Pfizer - Approval of Eucrisa to Drive Growth in the Dermatology Therapy Area 98
6.1.6 Celgene - Otezla Expected to Achieve Blockbuster Status in the Therapy Area 99
6.2 Company Landscape 100
6.3 Marketed and Pipeline Portfolio Analysis 102
7 Strategic Consolidations 104
7.1 Licensing Deals 104
7.1.1 Deals by Region, Year and Value 104
7.1.2 Deals by Stage of Development and Value 107
7.1.3 Deals by Molecule Type, Mechanism of Action and Value 107
7.1.4 Figures for Licensing Deals Valued Above $100m 109
7.2 Co-development Deals 112
7.2.1 Deals by Region, Year and Value 112
7.2.2 Deals by Stage of Development and Value 115
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 116
7.2.4 Figures for Co-development Deals Valued Above $100m 117
8 Appendix 119
8.1 References 119
8.2 Table of Epidemiology Forecast 125
8.3 Figure of All Clinical Stage Psoriasis ,Atopic dermatitis and Acne vulgaris Pipeline Products 126
8.4 Abbreviations 133
8.5 Disease List 134
8.6 Methodology 134
8.6.1 Coverage 134
8.6.2 Secondary Research 134
8.6.3 Market Size and Revenue Forecasts 135
8.6.4 Pipeline Analysis 135
8.6.5 Competitive Landscape 136
8.7 Contact Us 136
8.8 Disclaimer 136

List of Tables
1.1 List of Tables
Table 1: Dermatology, Global, Classification of Atopic Dermatitis Severity and Impact on Quality of Life 16
Table 2: Dermatology, Global, European Dermatology Forum Acne Vulgaris Classification 16
Table 3: Dermatology, Global, Classification of Acne Vulgaris Severity 17
Table 4: Dermatology, Global, Classification of Psoriasis Severity 17
Table 5: Dermatology, Global, Epidemiology of Dermatological Disorders, 2016 18
Table 6: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Humira, 2017 28
Table 7: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Remicade, 2017 29
Table 8: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Enbrel, 2017 31
Table 9: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Stelara, 2017 33
Table 10: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Neoral, 2017 35
Table 11: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Protopic, 2017 36
Table 12: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Cosentyx, 2017 38
Table 13: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Dupixent, 2017 39
Table 14: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Taltz, 2017 41
Table 15: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Eucrisa, 2017 43
Table 16: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Siliq, 2017 44
Table 17: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elidel, 2015 46
Table 18: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elocon, 2015 46
Table 19: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Differin, 2015 47
Table 20: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Metolate, 2017 48
Table 21: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Clobex, 2017 49
Table 22: Dermatology Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2016-2023 80
Table 23: Dermatology, Global, Usage of Generics Across Key Indications, 2017 82
Table 24: Dermatology Therapeutics Market, Global, Forecast Revenue by Company, 2016-2023 90
Table 25: Epidemiology Patterns for Atopic Dermatitis, 2015-2022 125
Table 26: Epidemiology Patterns for Acne Vulgaris, 2015-2022 125
Table 27: Epidemiology Patterns for Psoriasis, 2015-2022 125
Table 28: Abbreviations 133

List of Figures
1.2 List of Figures
Figure 1: Epidemiology Patterns for Atopic Dermatitis (million), 2016-2023 19
Figure 2: Epidemiology Patterns for Acne Vulgaris (million), 2016-2023 20
Figure 3: Epidemiology Patterns for Psoriasis (million), 2016-2023 21
Figure 4: Dermatology, Global, Key Marketed Products and Approved Indications, 2017 27
Figure 5: Dermatology Therapeutics Market, Global, Annual Revenue for Humira ($bn), 2006-2023 29
Figure 6: Dermatology Therapeutics Market, Global, Johnson & Johnson’s Annual Revenue for Remicade ($bn), 2006-2023 30
Figure 7: Dermatology Therapeutics Market, Global, Merck & Co.’s Annual Revenue for Remicade ($bn), 2010-2023 31
Figure 8: Dermatology Therapeutics Market, Global, Amgen’s Annual Revenue for Enbrel ($bn), 2006-2023 32
Figure 9: Dermatology Therapeutics Market, Global, Pfizer’s Annual Revenue for Enbrel ($bn), 2010-2023 33
Figure 10: Dermatology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010-2023 34
Figure 11: Dermatology Therapeutics Market, Global, Annual Revenue for Neoral ($m), 2006-2023 36
Figure 12: Dermatology Therapeutics Market, Global, Annual Revenue for Protopic ($m), 2006-2015 37
Figure 13: Dermatology Therapeutics Market, Global, Revenue Forecast for Cosentyx ($bn), 2016-2023 39
Figure 14: Dermatology Therapeutics Market, Global, Revenue Forecast for Dupilumab ($bn), 2017-2023 40
Figure 15: Dermatology Therapeutics Market, Global, Revenue Forecast for Taltz ($bn), 2017-2023 41
Figure 16: Dermatology Therapeutics Market, Global, Revenue Forecast for Taltz ($bn), 2016-2023 42
Figure 17: Dermatology Therapeutics Market, Global, Revenue Forecast for Eucrisa ($bn), 2016-2023 44
Figure 18: Dermatology Therapeutics Market, Global, Revenue Forecast for AMG-827 ($m), 2016-2022 45
Figure 19: Dermatology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 50
Figure 20: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Stage of Development, Molecule Type and Program Type, 2017 52
Figure 21: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Stage of Development, 2017 53
Figure 22: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecule Type, 2017 54
Figure 23: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2017 55
Figure 24: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2017 55
Figure 25: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecular Target, 2017 56
Figure 26: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2017 57
Figure 27: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016 58
Figure 28: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016 59
Figure 29: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016 60
Figure 30: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017 61
Figure 31: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2017 62
Figure 32: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016 63
Figure 33: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016 64
Figure 34: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016 65
Figure 35: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016 66
Figure 36: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016 67
Figure 37: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016 68
Figure 38: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016 69
Figure 39: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016 70
Figure 40: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016 71
Figure 41: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2017 72
Figure 42: Dermatology Therapeutics Market, Global, Revenue Forecast for Risankizumab ($m), 2016-2022 73
Figure 43: Dermatology Therapeutics Market, Global, Revenue Forecast for Zorblisa ($m), 2017-2023 75
Figure 44: Dermatology Therapeutics Market, Global, Revenue Forecast for Olumacostat glasaretil ($m), 2019-2023 76
Figure 45: Dermatology Therapeutics Market, Global, Revenue Forecast for Guselkumab ($m), 2016-2022 77
Figure 46: Dermatology Global, Market Size ($bn), 2016-2023 79
Figure 47: Dermatology Global, Annual Revenue Forecast for Key Products ($bn), 2016-2023 81
Figure 48: Dermatology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2016-2023 83
Figure 49: Dermatology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015-2022 84
Figure 50: Dermatology, Global, Annual Revenue Forecast for Calcineurin Inhibitors ($bn), 2015-2022 85
Figure 51: Dermatology, Global, Annual Revenue Forecast for Glucocorticosteroids ($m), 2015-2022 86
Figure 52: Dermatology, Global, Annual Revenue Forecast for Phosphodiesterase 4 inhibitors ($bn), 2015-2023 87
Figure 53: Dermatology Therapeutics Market, Global, Cluster by Growth and Market Share, 2016-2023 88
Figure 54: Dermatology Therapeutics Market, Global, Forecast Market Share by Company (%), 2016-2023 92
Figure 55: Dermatology, Global, Companies by Compound Annual Growth Rate (%), 2016-2023 93
Figure 56: Dermatology, Global, Revenues by Product Type, 2016-2023 94
Figure 57: Dermatology, Global, Novartis, Annual Revenue Forecast ($bn), 2016-2023 95
Figure 58: Dermatology, Global, AbbVie Annual Revenue Forecast ($bn), 2016-2023 96
Figure 59: Dermatology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015-2022 97
Figure 60: Dermatology, Global, Sanofi, Annual Revenue Forecast ($bn), 2015-2022 98
Figure 61: Dermatology, Global, Pfizer Annual Revenue Forecast ($bn), 2015-2022 99
Figure 62: Dermatology, Global, Celgene Annual Revenue Forecast ($bn), 2016-2023 100
Figure 63: Dermatology, Global, Companies by Type, 2017 101
Figure 64: Dermatology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Dermatology Specialization, 2017 102
Figure 65: Dermatology, Global, Proportion of Total Company Revenue Attributed to Dermatology, 2015-2022 103
Figure 66: Dermatology, Global, Licensing Deals, 2006-2017 105
Figure 67: Dermatology, Global, Licensing Deals by Indication, 2006-2017 106
Figure 68: Dermatology, Global, Licensing Deals, 2006-2017 107
Figure 69: Dermatology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2017 108
Figure 70: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 1) 109
Figure 71: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 2) 110
Figure 72: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 3) 111
Figure 73: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2017 (Part 4) 112
Figure 74: Dermatology, Global, Co-development Deals, 2006-2017 113
Figure 75: Dermatology, Global, Co-development Deals by Indication, 2006-2017 114
Figure 76: Dermatology, Global, Co-development Deals, 2006-2017 115
Figure 77: Dermatology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2017 116
Figure 78: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 1) 117
Figure 79: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 2) 117
Figure 80: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 3) 117
Figure 81: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2017 (Part 4) 118
Figure 82: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 1 126
Figure 83: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 2 127
Figure 84: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 3 128
Figure 85: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 4 129
Figure 86: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 5 130
Figure 87: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 6 131
Figure 88: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 Part 7 132

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".